The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax

European Cytokine Network

Volumn 16, Issue 2, 2005, Pages 123-127

  Wittnebel, S ^a   Jalil, A ^a   Thiery, J ^a   DaRocha, S ^a   Viey, E ^a   Escudier, B ^a   Chouaib, S ^a   Caignard, A ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bax; Interferon ; p53; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; HLA ANTIGEN CLASS 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; GAMMA IRRADIATION; GENOTOXICITY; HEPATOBLASTOMA; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MITOCHONDRION; PROTEIN EXPRESSION; WESTERN BLOTTING; BIOSYNTHESIS; CONFOCAL MICROSCOPY; FLUORESCENCE MICROSCOPY; KIDNEY TUMOR; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 32944468321     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Martel CL, Lara PN. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 2003; 45: 177.
2. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27: 177.
3. George CM, Stadler WM. The role of systemic chemotherapy in the treatment of kidney cancer. Cancer Treat Res 2003; 116: 173.
4. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44: 65.
5. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001; 19: 148.
6. Fishman M, Seigne J. Immunotherapy of metastatic renal cell cancer. Cancer Control 2002; 9: 293.
7. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408.
8. Sen GC, Lengyel P. The interferon system. A bird's eye view of its biochemistry. J Biol Chem 1992; 267: 5017.
9. Nathan PD, Eisen TG. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol 2002; 3: 89.
10. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424: 516.
11. Vilcek J. Boosting p53 with interferon and viruses. Nat Immunol 2003; 4: 825.
12. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18: 7621.
13. Shen Y, White E. p53-dependent apoptosis pathways. Adv Cancer Res 2001; 82: 55.
14. Thiery J, Dorothee G, Haddada H, et al. Potentiation of a tumor cell susceptibility to autologous CTL killing by restoration of wild-type p53 function. J Immunol 2003; 170: 5919.
15. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004; 64: 1951.
16. Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002; 13: 1460.
17. Caraglia M, Marra M, Pelaia G, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 2004: 9.
18. Brinckmann A, Axer S, Jakschies D, et al. Interferon-alpha resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1, which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells. Br J Cancer 2002; 86: 449.
19. Frank MH, Pomer S. Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype. J Cancer Res Clin Oncol 1999; 125: 117.
20. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002; 38: 167.
21. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 2000; 60: 2912.
22. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305: 626.
23. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010.
24. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 2004; 24: 6728.